The weekly litigation news digest is live. Subscribe now

IP Verse

Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor - EP3142661

The patent EP3142661 was granted to Astrazeneca on Oct 6, 2021. The application was originally filed on May 14, 2015 under application number EP15726257A. The patent is currently recorded with a legal status of "Revoked".

EP3142661

ASTRAZENECA
Application Number
EP15726257A
Filing Date
May 14, 2015
Status
Revoked
Jun 14, 2024
Publication Date
Oct 6, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKJul 6, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS6515117
INTERNATIONAL-SEARCH-REPORTUS6774112
INTERNATIONAL-SEARCH-REPORTWO2009091082
INTERNATIONAL-SEARCH-REPORTWO2010092125
INTERNATIONAL-SEARCH-REPORTWO2014161918

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents